Zai Lab (Hong Kong), Ltd.
Clinical trials sponsored by Zai Lab (Hong Kong), Ltd., explained in plain language.
A biopharmaceutical company developing and commercializing medicines for oncology and autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Can a gel tame psoriasis? new antibody fragment put to the test
Disease control Stopped earlyThis phase 2 trial is testing whether a topical gel containing ZL-1102, an antibody fragment that blocks IL-17A, can safely and effectively reduce the severity of chronic plaque psoriasis. The study enrolls adults with psoriasis for at least six months and compares different dose…
Phase 2 • Sponsor: Zai Lab (Hong Kong), Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo tested for tough cancers
Disease control Stopped earlyThis early-stage study tested a new drug called ZL-1218, alone or with another cancer drug, in 34 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, side effects, and how the drug moves through the body. The …
Phase 1 • Sponsor: Zai Lab (Hong Kong), Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC